ARID1A is mutated in 10% of intraductal papillary mucinous neoplasms (IPMNs) [101] and 6% of pancreatic adenocarcinoma (PDAC) [102], while KRAS mutations are found in more than 95% of pancreatic ductal adenocarcinoma (PDAC) [102]. This evidence concerns the gene ARID1A and pancreatic adenocarcinoma.